877-202-0205     support@chemchart.com     @chemchart
        
Sign In    Register
   Reset Filters

Pyrimidines, Drugs acting on the cardiovascular system

Categories

Cyclic compounds (6)
Six-membered rings (6)
Antihypertensive agents (3)
Pharmaceuticals (3)
Alpha blockers (2)
Alpha-2 blockers (2)
Aromatic compounds (2)
Cardiovascular system drug (2)
Drugs acting on the genito-urinary system (2)
Drugs for benign prostatic hyperplasia (2)
Piperazines (2)
Urologicals (2)
Acids (1)
Antiarrhythmic agents (1)
Antineoplastic and immunomodulating drug (1)
Antineoplastic and immunomodulating drugs (1)
Antiparkinsonian agents (1)
Carboxylic acids (1)
Dopamine agonists (1)
Drugs acting on the nervous system (1)
Five-membered rings (1)
Fluoroarenes (1)
Hypolipidemic agents (1)
Imidazolines (1)
Nitrobenzenes (1)
Organic acids (1)
Potassium channel blockers (1)
Psychoactive drugs (1)
Statins (1)

Suppliers

AK Scientific (3)
TCI Chemicals (3)
Sigma Aldrich (2)
Apollo Scientific (1)
Frontier Scientific (1)
Matrix Scientific (1)
Oakwood Chemical (1)
SynQuest Laboratories (1)

MOXONIDINE (75438-57-2)  
Moxon  ·  Zint  ·  Cynt
Moxonidine (INN) is a new-generation centrally acting antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. It may have a role when thiazides, beta-blockers, ACE inhibitors and calcium channel blockers are not appropriate or have failed to control blood pressure. In addition, it demonstrates favourable effects on parameters of the insulin resistance syndrome, apparently independent of blood pressure reduction.
Darusentan (171714-84-4)  
Darusentan (LU-135252; HMR-4005) is an endothelin receptor antagonist. Gilead Colorado, a subsidiary of Gilead Sciences, under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension. In June 2003, Myogen licensed the compound from Abbott for its application in the cancer field.
piribedil (3605-01-4)  
ET 495  ·  Trivastal  ·  Piribedil Mesylate
Piribedil (trade names Pronoran, Trivastal Retard, Trastal, Trivastan, Clarium and others) is an antiparkinsonian agent and piperazine derivative which acts as a D2 and D3 receptor agonist. It also has α2-adrenergic antagonist properties.
2-(1-Piperazinyl)pyrimidine (125523-53-7, 20980-22-7)  
MJ-13653  ·  1-(2-pyrimidinyl)piperazine  ·  MJ 13653
1-(2-Pyrimidinyl)piperazine (1-PP, 1-PmP) is a chemical compound and piperazine derivative. It is known to act as an antagonist of the α2-adrenergic receptor (Ki = 7.3–40 nM) and, to a much lesser extent, as a partial agonist of the 5-HT1A receptor (Ki = 414 nM; Emax = 54%). It has negligible affinity for the dopamine D2, D3, and D4 receptors (Ki > 10,000 nM) and does not appear to have significant affinity for the α1-adrenergic receptors.
nifekalant (130636-43-0)  
nifekalant hydrochloride  ·  MS-551  ·  1,3-dimethyl-6-((2-(N-(2-hydroxyethyl)-3-(4-nitrophenyl)propylamino)ethylamino)-2,4(1H),3H)-pyrimidinedione hydrochloride
Nifekalant (INN) is a class III antiarrhythmic agent approved in Japan for the treatment of arrhythmias and ventricular tachycardia. It has the brand name Shinbit.
Related searches
Pyrimidines
Drugs acting on the cardiovascular system